Inhibition of HIV-1 infection by the β-chemokine MDC

Science

Volumn 278, Issue 5338, 1997, Pages 695-698

  Pal, Ranajit ^a   Garzino Demo, Alfredo ^b   Markham, Phillip D ^a   Burns, Jennifer ^c   Brown, Michelle ^a   Gallo, Robert C ^b   DeVico, Anthony L ^b  

^a ADVANCED BIOSCIENCE LABORATORIES INC   (United States)

^b UNIVERSITY OF MARYLAND   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; CHEMOKINE;

ARTICLE; CELLULAR IMMUNITY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN T CELL LEUKEMIA VIRUS 1; MACROPHAGE FUNCTION; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; VIRUS CELL TRANSFORMATION; VIRUS INFECTION;

AMINO ACID SEQUENCE; ANTIVIRAL AGENTS; BLOTTING, NORTHERN; CALCIUM; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE; CELL LINE, TRANSFORMED; CELLS, CULTURED; CHEMOKINES, CC; HIV CORE PROTEIN P24; HIV INFECTIONS; HIV-1; HUMANS; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE ACTIVATION; RECEPTORS, CHEMOKINE; RECEPTORS, HIV; T-LYMPHOCYTES;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN T-LYMPHOTROPIC VIRUS 1;

EID: 0030722896     PISSN: 00368075     EISSN: None     Source Type: Journal    
DOI: 10.1126/science.278.5338.695     Document Type: Article

References (56)

1. C. M. Walker, D. J. Moody, D. P. Stites, J. A. Levy, Science 234, 1563 (1986); J. E. Brinchman et al., J. Immunol. 144, 2961 (1990).
2. C. M. Walker, D. J. Moody, D. P. Stites, J. A. Levy, Science 234, 1563 (1986); J. E. Brinchman et al., J. Immunol. 144, 2961 (1990).
3. C. M. Walker, D. Moody, D. P. Stites, J. A. Levy, Cell. Immunol. 119, 470 (1989); C. E. Mackewicz, H. W. Ortega, J. S. Levy, J. Clin. Invest. 87, 1462 (1991); D. J. Blackbourn et al., Proc. Natl. Acad. Sci. U.S.A. 93, 13125 (1996).
4. C. M. Walker, D. Moody, D. P. Stites, J. A. Levy, Cell. Immunol. 119, 470 (1989); C. E. Mackewicz, H. W. Ortega, J. S. Levy, J. Clin. Invest. 87, 1462 (1991); D. J. Blackbourn et al., Proc. Natl. Acad. Sci. U.S.A. 93, 13125 (1996).
5. C. M. Walker, D. Moody, D. P. Stites, J. A. Levy, Cell. Immunol. 119, 470 (1989); C. E. Mackewicz, H. W. Ortega, J. S. Levy, J. Clin. Invest. 87, 1462 (1991); D. J. Blackbourn et al., Proc. Natl. Acad. Sci. U.S.A. 93, 13125 (1996).
6. F. Cocchi et al., Science 270, 1811 (1996).
7. T. D. Barker, D. Weissman, J. A. Daucher, K. Roche, A. Fauci, J. Immunol. 156, 4476 (1996); X. Paliard, A. Y. Lee, C. M. Walker, AIDS 10, 1317 (1996); A. L. Kinter et al., Proc. Natl. Acad. Sci. U.S.A. 93, 14076 (1996); A. Rubbert et al., AIDS Res. Hum. Retroviruses 13, 63 (1997).
8. T. D. Barker, D. Weissman, J. A. Daucher, K. Roche, A. Fauci, J. Immunol. 156, 4476 (1996); X. Paliard, A. Y. Lee, C. M. Walker, AIDS 10, 1317 (1996); A. L. Kinter et al., Proc. Natl. Acad. Sci. U.S.A. 93, 14076 (1996); A. Rubbert et al., AIDS Res. Hum. Retroviruses 13, 63 (1997).
9. T. D. Barker, D. Weissman, J. A. Daucher, K. Roche, A. Fauci, J. Immunol. 156, 4476 (1996); X. Paliard, A. Y. Lee, C. M. Walker, AIDS 10, 1317 (1996); A. L. Kinter et al., Proc. Natl. Acad. Sci. U.S.A. 93, 14076 (1996); A. Rubbert et al., AIDS Res. Hum. Retroviruses 13, 63 (1997).
10. T. D. Barker, D. Weissman, J. A. Daucher, K. Roche, A. Fauci, J. Immunol. 156, 4476 (1996); X. Paliard, A. Y. Lee, C. M. Walker, AIDS 10, 1317 (1996); A. L. Kinter et al., Proc. Natl. Acad. Sci. U.S.A. 93, 14076 (1996); A. Rubbert et al., AIDS Res. Hum. Retroviruses 13, 63 (1997).
11. H. Moriuchi et al., Proc. Natl. Acad. Sci. U.S.A. 93, 15341 (1996).
12. + phenotype of the immortalized cell lines was verified by flow cytometry with antibodies to CD8 and to CD4 (Becton-Dickinson, San Jose, CA).
13. + phenotype of the immortalized cell lines was verified by flow cytometry with antibodies to CD8 and to CD4 (Becton-Dickinson, San Jose, CA).
14. 50 in PHA-stimulated normal PBMCs.
15. R. I. Connor et al., J. Exp. Med. 185, 621 (1997).
16. T. Dragic et al., Nature 381, 661 (1996); G. Alkhatib et al., Science 272, 1955 (1996); H. Deng et al., Nature 381, 661 (1996).
17. T. Dragic et al., Nature 381, 661 (1996); G. Alkhatib et al., Science 272, 1955 (1996); H. Deng et al., Nature 381, 661 (1996).
18. T. Dragic et al., Nature 381, 661 (1996); G. Alkhatib et al., Science 272, 1955 (1996); H. Deng et al., Nature 381, 661 (1996).
19. M. Jansson et al., Proc. Natl. Acad. Sci. U.S.A. 93, 15382 (1996).
20. 2O containing 0.1% TFA, and fractionated under the same conditions to obtain a single protein peak. The fraction corresponding to the peak and flanking fractions were tested in the infectivity assay to verify that suppressor activity cofractionated with the protein.
21. D. P. Witt and A. D. Lander, Curr. Biol. 4, 394 (1994); P. Proost et al., Methods 10, 82 (1996).
22. D. P. Witt and A. D. Lander, Curr. Biol. 4, 394 (1994); P. Proost et al., Methods 10, 82 (1996).
23. A. L. DeVico and R. Pal, unpublished data.
24. 2-terminal microsequencing was performed by automated Edman degradation with a Hewlett-Packard G1005A protein sequencing system, which was operated with standard reagents, solvents, and programs (routine 3.0) supplied by the manufacturer. Abbreviations for the amino acid residues are A, Ala; D, Asp; E, Glu; G, Gly; L, Leu; M, Met; N, Asn; P, Pro; R, Arg; S, Ser; V, Val; and Y, Tyr.
25. R. Godiska et al., J. Exp. Med. 185, 1595 (1997).
26. I. Lindley et al., Proc. Natl. Acad. Sci. U.S.A. 85, 9199 (1988); T. Yoshimura et al., Mol. Immunol. 26, 87 (1989); J. VanDamme et al., Eur. J. Biochem. 181, 337 (1989); C. A. Hebert et al., J. Immunol. 145, 3033 (1990).
27. I. Lindley et al., Proc. Natl. Acad. Sci. U.S.A. 85, 9199 (1988); T. Yoshimura et al., Mol. Immunol. 26, 87 (1989); J. VanDamme et al., Eur. J. Biochem. 181, 337 (1989); C. A. Hebert et al., J. Immunol. 145, 3033 (1990).
28. I. Lindley et al., Proc. Natl. Acad. Sci. U.S.A. 85, 9199 (1988); T. Yoshimura et al., Mol. Immunol. 26, 87 (1989); J. VanDamme et al., Eur. J. Biochem. 181, 337 (1989); C. A. Hebert et al., J. Immunol. 145, 3033 (1990).
29. I. Lindley et al., Proc. Natl. Acad. Sci. U.S.A. 85, 9199 (1988); T. Yoshimura et al., Mol. Immunol. 26, 87 (1989); J. VanDamme et al., Eur. J. Biochem. 181, 337 (1989); C. A. Hebert et al., J. Immunol. 145, 3033 (1990).
30. A. Walz and M. Baggiolini, J. Exp. Med. 171, 449 (1990); J. VanDamme et al., Eur. J. Immunol. 20, 2113 (1990); I. Clark-Lewis, C. Schumacher, M. Baggiolini, B. Moser, J. Biol. Chem. 266, 23128 (1991).
31. A. Walz and M. Baggiolini, J. Exp. Med. 171, 449 (1990); J. VanDamme et al., Eur. J. Immunol. 20, 2113 (1990); I. Clark-Lewis, C. Schumacher, M. Baggiolini, B. Moser, J. Biol. Chem. 266, 23128 (1991).
32. A. Walz and M. Baggiolini, J. Exp. Med. 171, 449 (1990); J. VanDamme et al., Eur. J. Immunol. 20, 2113 (1990); I. Clark-Lewis, C. Schumacher, M. Baggiolini, B. Moser, J. Biol. Chem. 266, 23128 (1991).
33. S. C. Bischoff et al., Eur. J. Immunol. 23, 761 (1993); M. Baggiolini, B. Dewald, B. Moser, Adv. Immunol. 55, 97 (1994); K. B. Bacon, B. A. Premack, P. Gardner, T. J. Schall, Science 269, 1727 (1995).
34. S. C. Bischoff et al., Eur. J. Immunol. 23, 761 (1993); M. Baggiolini, B. Dewald, B. Moser, Adv. Immunol. 55, 97 (1994); K. B. Bacon, B. A. Premack, P. Gardner, T. J. Schall, Science 269, 1727 (1995).
35. S. C. Bischoff et al., Eur. J. Immunol. 23, 761 (1993); M. Baggiolini, B. Dewald, B. Moser, Adv. Immunol. 55, 97 (1994); K. B. Bacon, B. A. Premack, P. Gardner, T. J. Schall, Science 269, 1727 (1995).
36. 6) were then added to sample tubes, loaded for 20 min at 37°C with 2 μM fluo-3 (Molecular Probes) reconstituted in a solution containing 20% Pluronic F-127 (Molecular Probes) and dimethyl sulfoxide, and stained with 7-aminoactinomycin D (Molecular Probes) to discriminate dead cells [I. Schmid et al., Cytometry 13, 204 (1992)]. The samples were then washed once as before and resuspended in 1 ml of RPMI 1640 without phenol red and sodium bicarbonate. All samples were maintained at 20°C in the dark until 5 min before analysis, at which time the sample tube was placed in a 37°C water bath. Cells were maintained at 37°C throughout data acquisition. Cells were stimulated by addition of test chemokine to a final concentration of 3 nM. Data were acquired with a FACSCalibur (Becton-Dickinson) flow cytometer, with excitation at 488 nm. Cells were gated by forward-and side-scatter properties as well as by exclusion of 7-aminoactinomycin D fluorescence by use of emission above 650 nm in the FL-3 window. Calcium mobilization was determined by a two-parameter density plot of linear emissions collected at 530 nm in the FL-1 window for the gated cell population over time.
37. 6) were then added to sample tubes, loaded for 20 min at 37°C with 2 μM fluo-3 (Molecular Probes) reconstituted in a solution containing 20% Pluronic F-127 (Molecular Probes) and dimethyl sulfoxide, and stained with 7-aminoactinomycin D (Molecular Probes) to discriminate dead cells [I. Schmid et al., Cytometry 13, 204 (1992)]. The samples were then washed once as before and resuspended in 1 ml of RPMI 1640 without phenol red and sodium bicarbonate. All samples were maintained at 20°C in the dark until 5 min before analysis, at which time the sample tube was placed in a 37°C water bath. Cells were maintained at 37°C throughout data acquisition. Cells were stimulated by addition of test chemokine to a final concentration of 3 nM. Data were acquired with a FACSCalibur (Becton-Dickinson) flow cytometer, with excitation at 488 nm. Cells were gated by forward-and side-scatter properties as well as by exclusion of 7-aminoactinomycin D fluorescence by use of emission above 650 nm in the FL-3 window. Calcium mobilization was determined by a two-parameter density plot of linear emissions collected at 530 nm in the FL-1 window for the gated cell population over time.
38. 6) were then added to sample tubes, loaded for 20 min at 37°C with 2 μM fluo-3 (Molecular Probes) reconstituted in a solution containing 20% Pluronic F-127 (Molecular Probes) and dimethyl sulfoxide, and stained with 7-aminoactinomycin D (Molecular Probes) to discriminate dead cells [I. Schmid et al., Cytometry 13, 204 (1992)]. The samples were then washed once as before and resuspended in 1 ml of RPMI 1640 without phenol red and sodium bicarbonate. All samples were maintained at 20°C in the dark until 5 min before analysis, at which time the sample tube was placed in a 37°C water bath. Cells were maintained at 37°C throughout data acquisition. Cells were stimulated by addition of test chemokine to a final concentration of 3 nM. Data were acquired with a FACSCalibur (Becton-Dickinson) flow cytometer, with excitation at 488 nm. Cells were gated by forward-and side-scatter properties as well as by exclusion of 7-aminoactinomycin D fluorescence by use of emission above 650 nm in the FL-3 window. Calcium mobilization was determined by a two-parameter density plot of linear emissions collected at 530 nm in the FL-1 window for the gated cell population over time.
39. 6) were then added to sample tubes, loaded for 20 min at 37°C with 2 μM fluo-3 (Molecular Probes) reconstituted in a solution containing 20% Pluronic F-127 (Molecular Probes) and dimethyl sulfoxide, and stained with 7-aminoactinomycin D (Molecular Probes) to discriminate dead cells [I. Schmid et al., Cytometry 13, 204 (1992)]. The samples were then washed once as before and resuspended in 1 ml of RPMI 1640 without phenol red and sodium bicarbonate. All samples were maintained at 20°C in the dark until 5 min before analysis, at which time the sample tube was placed in a 37°C water bath. Cells were maintained at 37°C throughout data acquisition. Cells were stimulated by addition of test chemokine to a final concentration of 3 nM. Data were acquired with a FACSCalibur (Becton-Dickinson) flow cytometer, with excitation at 488 nm. Cells were gated by forward-and side-scatter properties as well as by exclusion of 7-aminoactinomycin D fluorescence by use of emission above 650 nm in the FL-3 window. Calcium mobilization was determined by a two-parameter density plot of linear emissions collected at 530 nm in the FL-1 window for the gated cell population over time.
40. PBMCs (American Red Cross) from a healthy donor were purified by centrifugation in Histopaque (Sigma) and harvested either immediately or after activation for 48 hours with PHA (5 μg/ml) and rIL-2 (10 ng/ml). The HUT 78 human T cell line was cultured in the presence (50 U/ml) or absence of IL-2 (Boehringer, Mannheim, Germany). RNA was isolated by the RNAzol procedure (Tel-Test, Friendswood, TX), and 10 μg of total cellular RNA was separated by electrophoresis on a denaturing formaldehyde-agarose gel and then transferred to a nylon membrane. The membrane was subjected to hybridization with an MDC-specific probe and washed under stringent conditions as described [A. Garzino-Demo, R. C. Gallo, S. K. Arya, Hum. Gene Ther. 6, 177 (1995)]. The probe for Northern hybridizations was generated by reverse transcription and polymerase chain reaction with MDC-specific primers.
41. A. Garzino-Demo, A. DeVico, R. Pal, unpublished results.
42. Y. Feng, C. C. Broder, P. E. Kennedy, E. A. Berger, Science 272, 872 (1996); H. Choe et al., Cell 85, 1135 (1996); B. J. Doranz et al., ibid., p. 1149; J. F. Berson et al., J. Virol. 70, 6288 (1996).
43. Y. Feng, C. C. Broder, P. E. Kennedy, E. A. Berger, Science 272, 872 (1996); H. Choe et al., Cell 85, 1135 (1996); B. J. Doranz et al., ibid., p. 1149; J. F. Berson et al., J. Virol. 70, 6288 (1996).
44. Y. Feng, C. C. Broder, P. E. Kennedy, E. A. Berger, Science 272, 872 (1996); H. Choe et al., Cell 85, 1135 (1996); B. J. Doranz et al., ibid., p. 1149; J. F. Berson et al., J. Virol. 70, 6288 (1996).
45. Y. Feng, C. C. Broder, P. E. Kennedy, E. A. Berger, Science 272, 872 (1996); H. Choe et al., Cell 85, 1135 (1996); B. J. Doranz et al., ibid., p. 1149; J. F. Berson et al., J. Virol. 70, 6288 (1996).
46. C. Bluel et al., Nature 382, 829 (1996); E. Oberlin et al., ibid., p. 833.
47. C. Bluel et al., Nature 382, 829 (1996); E. Oberlin et al., ibid., p. 833.
48. J. He et al., ibid. 385, 645 (1997).
49. L. Zhang, Y. Huang, T. He, Y. Cao, D. D. Ho, ibid. 383, 768 (1996); M. T. Dittmar et al., ibid. 385, 495 (1997); G. Simmons, J. Virol. 70, 8355 (1996).
50. L. Zhang, Y. Huang, T. He, Y. Cao, D. D. Ho, ibid. 383, 768 (1996); M. T. Dittmar et al., ibid. 385, 495 (1997); G. Simmons, J. Virol. 70, 8355 (1996).
51. L. Zhang, Y. Huang, T. He, Y. Cao, D. D. Ho, ibid. 383, 768 (1996); M. T. Dittmar et al., ibid. 385, 495 (1997); G. Simmons, J. Virol. 70, 8355 (1996).
52. S. Patterson and S. C. Knight, J. Gen. Virol. 68, 1177 (1987); J. Embretson et al., Nature 362, 359 (1993); M. Pope et al., J. Exp. Med. 182, 2045 (1995).
53. S. Patterson and S. C. Knight, J. Gen. Virol. 68, 1177 (1987); J. Embretson et al., Nature 362, 359 (1993); M. Pope et al., J. Exp. Med. 182, 2045 (1995).
54. S. Patterson and S. C. Knight, J. Gen. Virol. 68, 1177 (1987); J. Embretson et al., Nature 362, 359 (1993); M. Pope et al., J. Exp. Med. 182, 2045 (1995).
55. A. Granelli-Piperno et al., J. Exp. Med. 184, 2433 (1996).
56. We thank B. Lambe for technical assistance; A. Wiznia, G. Lambert, M. Rosenberg, J. Dobroszycki, and O. Cohen for clinical samples; N. Miller for helpful discussions and support for our search for new HIV-1-suppressor chemokines; K. Swiderek for amino acid analysis and microsequencing; and R. Connor for primary virus isolates. R.P., M.B., and P.D.M. were supported in part by National Institute of Allergy and Infectious Diseases contract NO1-AI-55279 to Advanced BioScience Laboratories.